Long|term persistence of TNF|inhibitor treatment in patients with ...

Long-term persistence of TNF-inhibitor treatment in patients with ...

We found good long-term persistence of TNFi in this PsA population both for the first and subsequent TNFi treatments. The relationship between persistence ...

Long-term persistence of TNF-inhibitor treatment in patients with ...

In conclusion, we find that almost half of all patients with PsA starting their first TNFi during the first 5 years of TNFi availability in the ...

Effectiveness and persistence of anti-TNFα treatment in patients with

A higher proportion of patients had moderate or high disease activity for all three anti-TNFα. In first-year treatment, 67% to 87% of the cohort ...

Long-term persistence of TNF-inhibitor treatment in patients with ...

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the ...

Long- term effectiveness and persistence of ustekinumab and TNF ...

on treatment persistence, effectiveness and safety of biological therapy in patients with PsA. Overall, for ustekinumab and TNFi treatments ...

(PDF) Long-term persistence of TNF-inhibitor treatment in patients ...

Conclusion We found good long-term persistence of TNFi in this PsA population both for the first and subsequent TNFi treatments. The relationship between ...

Long-term Persistence of First-line Biologics for Psoriasis and ...

After inverse probability of treatment weighting and adjustments, IL-17 inhibitors were associated with higher persistence than TNF inhibitors ...

Long-term effectiveness of tumour necrosis factor-α inhibitor ...

Long-term TNFi therapy is well tolerated and may be effective in ≥50% of patients based on TNFi persistence. However, changing to an alternative ...

Factors associated with cause-specific discontinuation of long-term ...

AS patients on their first anti-TNF treatment for at least two years demonstrated a favorable long-term treatment retention rate, with a ...

Long-term TNF-inhibitor treatment in patients with psoriatic arthritis.

Full title: Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics ...

Persistence with anti-tumour necrosis factor therapies in patients ...

Anti-TNF therapies represent a breakthrough in the treatment of severe psoriatic arthritis. However, little is known about long-term drug ...

Efficacy and Safety of TNF Inhibitors in the Treatment of RA

Patients (n = 1242) analyzed included 39.4% receiving infliximab/MTX, 48% etanercept/MTX, and 11.7% ADA/MTX. The persistence rate on infliximab was 78%, ...

Persistence of tumor necrosis factor inhibitor or conventional ...

Among the evaluable patients with existing TNFi monotherapy (n = 251), csDMARD monotherapy (n = 225), and combination therapy (n = 214), 93, 87, ...

Patient characteristics associated with use of TNF vs interleukin ...

However, use of TNF inhibitors was associated with a greater treatment persistence with high adherence compared with use of IL-12/23 or 17 ...

Five-year treatment retention data pooled from pivotal Phase III ...

Probability of long-term golimumab treatment retention with 2nd-line therapy, while lower than that of 1st-line therapy, also remained favorable ...

Prevalence and predictors of tumour necrosis factor inhibitor ...

Persistence with TNFi therapy in second-line users ... A total of 32 patients had switched to using a second TNFi (59% to adalimumab, 41% to ...

Long‐Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A ...

Pooled drug survival rates after 60 months follow-up were 37% (infliximab), 48% (adalimumab), and 52% (etanercept). Further, in an observational ...

Long-term Persistence of Second-line Biologics in Psoriatic Arthritis ...

Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA).

[PDF] Treatment persistence of subcutaneous TNF inhibitors among ...

There is variance in real-world persistence to TNFi in patients with immune-mediated rheumatic disease by line of therapy, with the time on therapy ...

Safety of Guselkumab With and Without Prior Tumor Necrosis Factor ...

Among all GUS-treated patients (including those who crossed over from PBO), low AE rates were maintained during long-term evaluation in both ...